<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2590">
  <stage>Registered</stage>
  <submitdate>25/11/2009</submitdate>
  <approvaldate>25/11/2009</approvaldate>
  <nctid>NCT01020916</nctid>
  <trial_identification>
    <studytitle>Target Temperature Management After Cardiac Arrest</studytitle>
    <scientifictitle>Target Temperature Management 33°C Versus 36°C After Out-of-hospital Cardiac Arrest, a Randomised, Parallel Groups, Assessor Blinded Clinical Trial</scientifictitle>
    <utrn />
    <trialacronym>TTM</trialacronym>
    <secondaryid>TTM-1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Out-of-hospital Cardiac Arrest</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Target temperature 36°C
Treatment: surgery - Target Temperature 33°C

Experimental: Target Temperature 33°C - 

Active Comparator: Target Temperature 36°C - 


Treatment: surgery: Target temperature 36°C
In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours

Treatment: surgery: Target Temperature 33°C
In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>Maximum follow-up with a minimum of 180 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Composite outcome of all-cause mortality and poor neurological function (CPC 3 and 4) and composite outcome of all-cause mortality and poor neurological function (modified Rankin Scale 4 and 5)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bleeding</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurological function - Cerebral Performance Category, Modified Rankin Scale</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pneumonia</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Electrolyte disorders</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperglycaemia &gt; 10 mmol/l</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hypoglycemia &lt; 3mmol/l</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac arrhythmia</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The need for renal replacement therapy</outcome>
      <timepoint>During day 1-7 of intensive care treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark all-cause mortality</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cerebral Performance Category (CPC) - CPC 1,2,3,4,5</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modified Rankin Scale (mRS) - mRS 1,2,3,4,5,6</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age = 18 years old

          -  Out-of-hospital cardiac arrest (OHCA) of presumed cardiac cause

          -  Return of spontaneous circulation (ROSC)

          -  Unconsciousness (Glasgow Coma Score &lt; 8) (patients not able to obey verbal
             commands)after sustained ROSC</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  In-hospital cardiac arrest

          -  OHCA of presumed non-cardiac cause, e.g. after trauma or dissection/rupture of major
             artery OR Cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation,
             hanging).

          -  Known bleeding diathesis (medically induced coagulopathy (e.g warfarin, clopidogrel)
             does not exclude the patient).

          -  Suspected or confirmed acute intracranial bleeding

          -  Suspected or confirmed acute stroke

          -  Unwitnessed asystole

          -  Known limitations in therapy and Do Not Resuscitate-order

          -  Known disease making 180 days survival unlikely

          -  Known pre-arrest CPC 3 or 4

          -  Temperature &lt; 30°C on admission

          -  &gt; 4 hours (240 minutes) from ROSC to screening

          -  Systolic blood pressure &lt; 80 mm Hg in spite of fluid loading/vasopressor and/or
             inotropic medication/intra aortic balloon pump#

               -  If the systolic blood pressure (SBP) is recovering during the inclusion window
                  (220 minutes) the patient can be included.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>950</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Liverpool Hospital - Sydney</hospital>
    <hospital>North Shore Hospital - Sydney</hospital>
    <hospital>St George Hospital - Sydney</hospital>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pordenone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Trieste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Luxembourg</country>
      <state>Luxembourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leeuwarden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Helsingborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Karlstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Kungälv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmö</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Norrköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Trollhättan/Vänersborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Örebro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Reading</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Niklas Nielsen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Scandinavian Critical Care Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Copenhagen Trial Unit, Center for Clinical Intervention Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Lund University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The George Institute for Global Health, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Experimental studies and previous clinical trials suggest an improvement in mortality and
      neurological function with hypothermia after cardiac arrest. However, the accrued evidence is
      inconclusive and associated with risks of systematic error, design error and random error.
      Elevated body temperature after cardiac arrest is associated with a worse outcome. Previous
      trials did not treat elevated body temperature in the control groups. The optimal target
      temperature for post-resuscitation care is not known. The primary purpose with the TTM-trial
      is to evaluate if there are differences in all-cause mortality, neurological function and
      adverse events between a target temperature management at 33°C and 36°C for 24 hours
      following return of spontaneous circulation after cardiac arrest.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01020916</trialwebsite>
    <publication>Nielsen N, Friberg H, Gluud C, Herlitz J, Wetterslev J. Hypothermia after cardiac arrest should be further evaluated--a systematic review of randomised trials with meta-analysis and trial sequential analysis. Int J Cardiol. 2011 Sep 15;151(3):333-41. doi: 10.1016/j.ijcard.2010.06.008. Epub 2010 Jul 1. Review.
Nielsen N, Hovdenes J, Nilsson F, Rubertsson S, Stammet P, Sunde K, Valsson F, Wanscher M, Friberg H; Hypothermia Network. Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. 2009 Aug;53(7):926-34. doi: 10.1111/j.1399-6576.2009.02021.x. Epub 2009 Jun 22.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Niklas Nielsen, MD, PhD</name>
      <address>Helsingborgs lasarett, Region Skåne, Sweden</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>